Mission Therapeutics, a Cambridge clinical-stage biotech focused on enhancing mitophagy, raised $13.3M in a financing led by its existing investors to advance its therapeutic programs. Lead investors include Pfizer Venture Investments, Sofinnova Partners, Roche Venture Fund, SR One, IP Group and Rosetta Capital.
Comments
Want to join the conversation?
Loading comments...